2022CSH Talents gather to climb the "peak" of blood scholarship! The 17th National Hematology Academic Conference of the Chinese Medical Association was successfully concluded

Listening to the sound of blood and perceiving the rhythm of life, the "17th National Hematology Academic Conference of the Chinese Medical Association" hosted by the Chinese Medical Association and the Hematology Branch of the Chinese Medical Association, hosted by the Shanghai Medical Association, co-organized by Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the First Affiliated Hospital of Soochow University, and the Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, was
held on September 23-25, 2022 at the National Convention and Exhibition Center in Shanghai.

The National Hematology Academic Conference is the largest and highest specification conference in the field of hematology in China, and is the most important academic activity of the Hematology Branch of the Chinese Medical Association, which not only provides a platform for hematology scientists active in the forefront of scientific research to exchange and discuss, but also a review
of the latest achievements in the development of domestic hematology.

With the theme of "respect, inheritance, collaboration and innovation", many well-known experts at home and abroad gathered together to present a wonderful academic feast
for the field of hematology in China.

Medical Pulse has compiled the wonderful content of this conference for the benefit of readers
.

Under the co-chairmanship of Professor Jin Jie of the First Affiliated Hospital of Zhejiang University School of Medicine and Professor Ji Chunyan of Qilu Hospital of Shandong University, Professor Daniel A.
Pollyea, Department of Hematology, University of Colorado, USA, shared the application
of Venecra treatment in patients with acute myeloid leukemia (AML).

AML therapy should stratify the prognosis of patients according to different risk factors, and older AML, patients with AML with gene mutations such as RUNX1, or patients with secondary AML are more likely to benefit
from the Venekla combination regimen than with intensive therapy.

Be open to drug selection under unconventional risk factors
.

Once risk factors are identified, a cautious approach to treatment is required, depending on the individual patient's condition or dose adjustment, or replacement
with the Venecra regimen.

In addition, Professor Polyea gave a detailed explanation
of the application of the Venekla Combination Programme in overcoming AML recurrence resistance, pre-transplant bridging therapy, and extension to Myelodysplastic Syndrome (MDS).

Professor Daniel A.
Polyea gave a wonderful presentation

Co-chaired by Professor Li Juan of the First Affiliated Hospital of Sun Yat-sen University and Professor Hou Jian of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Professor Philippe Moreau of the University Hospital Center of Nantes in France reported on
the application of new drugs in the induction therapy of multiple myeloma (MM), the importance of stratified treatment by age, the definition and monitoring of minimal residual disease (MRD), and the comparison of MM maintenance therapy programs.

For transplant-appropriate patients, there is a clear benefit
in ≥ complete response (CR) rates, MRD-negative rates, and progression-free survival (PFS) in the treatment of patients with high-risk cytogenetic abnormalities and international stage system (ISS) stage III disease prior to transplantation compared with VTd.

For patients who are not candidates for transplantation, the D-Rd, D-VMP, and VRd regimens are recommended on the
first line.

* V, bortezomib; T, thalidomide; d.

Professor Philippe Moreau gave a wonderful presentation

Under the co-chairmanship of Professor Song Yongping of the First Affiliated Hospital of Zhengzhou University and Professor Lai Yongrong of the First Affiliated Hospital of Guangxi Medical University, Professor Huang Xiaojun of Peking University People's Hospital looked forward
to the development of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the next ten years.

Professor Huang Xiaojun first believes that in the next decade, the proportion of patients with allo-HSCT will continue to increase, and the survival time of patients will be extended
as a result.

Haploid hematopoietic stem cell transplantation (Haplo-HSCT) will play a key role
in the development of allo-HSCT.

Second, a combination of targeted and immunotherapy will enhance allo-HSCT, thereby reducing disease recurrence or non-recurrence mortality and prolonging patient survival after HSCT
.

Chimeric antigen receptor T cell (CAR-T) therapy bridging allo-HSCT improves survival in patients with recurrent or refractory acute B-lymphoblastic leukemia (R/R B-ALL) and clears MRD
.

Finally, Professor Huang Xiaojun pointed out that human leukocyte antigen (HLA) incompatibility is no longer a factor in determining donor selection, but non-HLA genetic factors that determine donor selection in the future still need to be explored
.

Professor Huang Xiaojun made a wonderful report

Under the co-chairmanship of Professor Zhang Liansheng of the Second Hospital of Lanzhou University and Professor Zhang Xi of Xinqiao Hospital of Army Military Medical University, Professor Delong Liu of New York Medical College shared the insights on the
application of CAR-T, antibody drug conjugates (ADCs) and bispecific T cell conjugates (BiTE) in lymphoma treatment.

Professor Delong Liu first introduced the detailed process of in vivo transduction of CAR-T using viral constructs, the preparation of general-purpose CAR and CAR-T, and the comparison of the application of CAR-T and autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with R/R non-Hodgkin lymphoma (NHL), and noted that the major histocompatibility complex (MHC) limitations are eliminated in the preparation of general-purpose CAR-T cells, and knockout of endogenous T cell receptors and CD52 is important
.

Subsequently, Professor Delong Liu introduced the development process of Bellintoxumab, ADC drugs targeting CD19, CD22 or CD79b, and tafasitamab, and expressed expectations
for the combined use of the above drugs.

Professor Delong Liu gave a wonderful presentation

Under the co-chairmanship of Professor Chen Fangping of Xiangya Hospital of Central South University and Professor Niu Ting of West China Hospital of Sichuan University, Professor Wang Jianxiang of Hematology Hospital of Chinese Academy of Medical Sciences elaborated
on hematological tumor immunotherapy.

From the research and development of CAR-T cells of new targets to the exploration of new strategies to optimize the function of CAR-T cells, to the clinical research of CAR-T in the treatment of hematological tumors, Professor Wang Jianxiang and his team independently developed CD19 CAR-T products for the treatment of adult R/R ALL and NHL and children's R/R ALL were applied for
clinical trials of new drugs by the State Drug Administration (NMPA).

CD19CD22 CAR-T for B-ALL that has obtained independent intellectual property rights; Off-the-shelf anti-CD7 CAR-T for T-ALL; CD123CD33 CAR-T for AML, IL10 CAR-T; Therapies such as BCMA/CD38 CAR-T for MM have demonstrated their killing activity
against leukemia cells in in vitro and in vitro trials.

In addition, CAR-NK research is also underway, and several NK cell expansion systems have been explored, which are expected to meet clinical treatment needs in the
future.

Professor Wang Jianxiang made a wonderful report

Under the co-chairmanship of Professor Hou Ming of Qilu Hospital of Shandong University and Professor Yang Linhua of the Second Hospital of Shanxi Medical University, Professor Ni Heyu of St.
Michael's Hospital in Toronto, Canada introduced some thoughts
on new discoveries and opportunities for platelets.

Professor Ni Heyu explained in detail the mechanism of platelet adhesion and aggregation, and pointed out that in the absence of anticoagulants, fibrinogen is not necessary for platelet aggregation, and fibronectin plays a dual equilibrium role
of hemostasis and prevention of thrombosis.

In addition, platelets can also act as immune cells involved in immune system regulation and tumor cell metastasis
.

Professor Ni Heyu mentioned that if the interaction between tumor cells and platelets can be limited, it may provide a new window for clinical treatment of tumors and prolong the survival of patients, but this view still needs to be verified
by clinical trials.

Professor Ni Heyu made a wonderful report

Under the co-chairmanship of Professor Fu Rong of the General Hospital of Tianjin Medical University and Professor Liu Daihong of the General Hospital of the People's Liberation Army of Chinese, Professor Hu Yu of the Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology reported on the development of gene therapy for coagulation diseases
.

Although conventional methods can control the symptoms of hereditary coagulation diseases, they cannot achieve long-term treatment goals, but gene therapy is expected to repair abnormal genes and cure such diseases
.

For hemophilia, specific inhibition of heparin cofactor II (HCII) synthesis can re-establish the coagulation balance and improve hemostasis in patients, which is a safe and effective treatment strategy
.

For hereditary antithrombin (AT) deficiency, obtaining mutant cells from the patient's body, through induction-gene editing-differentiation-backtransfusion, can correct AT gene mutations, which has shown a tendency to prevent thrombosis in animal models, which is worth looking forward to
.

Professor Hu Yu made a wonderful report

Co-chaired by Professor Fang Meiyun of Zhongshan Hospital Affiliated to Dalian University and Professor Wang Jingwen of Beijing Tongren Hospital Affiliated to Capital Medical University, Professor Tang Fuzhi of the Center for Biomedical Frontier Innovation (BIOPIC) of the School of Life Sciences of Peking University gave a report
on the topic of "Exploring the Molecular Mechanism of Oncology Using Single-cell Sequencing Technology".

Professor Tang Fuzhi's research group used single-cell sequencing technology to conduct in-depth analysis of cancer tissue, lymph node metastatic tissue, paracancerous tissue and peripheral blood samples of coloral cancer patients, and found that genetic variation was widely present in various immune cells, fibroblasts and vascular endothelial cells in normal tissues
of the human body.

The proportion of fibroblasts with genetic abnormalities in tumor tissue is much higher than that of normal tissue next to cancer, and the proportion of genetically abnormal fibroblasts in tumor tissue undergoes significant clonal expansion
.

Tumor marker genes specifically expressed by fibroblasts in the tumor microenvironment, and their expression levels are closely related to colorectal cancer prognosis
.

Professor Tang Fuzhi made a wonderful report

Under the auspices of Professor Liang Aibin of Shanghai Tongji Hospital, Professor Zhao Weichen of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine announced the selected CSH papers selected from the abstracts of this conference
.

Professor Zhao Weicheng said that the 2022 CSH stars gathered, analyzed the details of molecular mechanisms, explored the practicality of clinical prognosis models, discussed the development of translational medicine, and looked forward to a bright future
in the field of hematology.

Once again, congratulations to the teams that have received the CSH Gathering Honor, and hope that everyone will continue to play an advantage in future work and promote the development
of the blood field.

Looking forward to the wonderful presentation of outstanding clinical research and translational medicine achievements at the National Hematology Academic Conference every year!

Prof.
Weiying Zhao publishes CSH Convergence Papers

Flag handover ceremony

Drumming urges steady driving boats, and strives to set sail to a new journey
.

The 17th National Hematology Academic Conference of the Chinese Medical Association was successfully concluded online and offline! The conference has effectively promoted academic exchanges in the field of hematology, promoted the construction and development of hematology disciplines, and brought more benefits
to patients with hematological tumors.

Facing the future, with a mission, shouldering responsibilities, striving forward, working together on the road of diagnosis and treatment of blood diseases, being a pioneer in the development of a higher level, higher level and higher quality of Chinese hematology, contributing wisdom and strength to jointly promoting the cause of human health, I believe that in the future, we will continue to strive to achieve the goal of "Healthy China 2030"
.

Poke "Read the original article" and go to the micro-official website to get more meeting information